Infliximab side effects Remicade medication
Infliximab is a pharmaceutical drug used to treat auto-immune disorders. Infliximab reduces the amount of active tumor necrosis factor alpha in the body by binding to it and preventing it from signaling the receptors for TNF alpha on the surface of cells. TNF alpha is one of the major cytokines that triggers and sustains the inflammation response. Infliximab was developed by Centocor, a pharmaceutical company owned by Johnson & Johnson.
Infliximab for rheumatoid
Infliximab is used with methotrexate and is initially administered intravenously at weeks 0, 2, and 6. Maintenance doses are then given every 8 weeks. For more information on rheumatoid arthritis.
Infliximab side effects, safety,
Mild infusion reactions include headache and nausea; severe infliximab side effects include chest pain, shortness of breath, hypotension, and urticaria or other evidence of an immediate hypersensitivity reaction.
Infliximab for ankylosing
Treatment with Infliximab in a patient with ankylosing spondylitis and Crohn's disease.
J Gastrointestin Liver Dis. 2006. Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Str. Clinicilor Cluj-Napoca, Romania;
The association of Crohn's disease and ankylosing spondylitis is described in up to 30% of cases. We present the case of a 53 year old woman, diagnosed with colonic Crohn's disease and ankylosing spondilitis, treated initially with increasing doses of sulphasalazine and moderate dose of corticosteroids, with the persistence of severe gastrointestinal and articular symptoms. She underwent therapy with tumor necrosis factor alpha (TNFalpha) inhibitor Infliximab, with a spectacular improvement of symptoms, signs and quality of life.
Infliximab for psoriasis
Infliximab has shown promising results for the treatment of severe psoriasis and may be considered in patients who are unresponsive to conventional systemic and biologic therapy. Infliximab may help patients with psoriasis previously treated with etanercept, but the majority of patients require infusions every 6 weeks to maintain their continued response. In addition, the use of infliximab is associated with increased incidence of adverse events.